摘要
目的:观察并比较度普利尤单抗治疗成年人和未成年人中重度特应性皮炎(AD)的有效性及安全性。方法:回顾性分析2020年3月至2024年10月在上海交通大学医学院附属仁济医院变态反应科或儿科诊断为中重度AD的80例患者资料,按年龄分为未成年组(37例)与成年组(43例),均使用度普利尤单抗治疗16周及以上,比较治疗前、后2组患者的各项临床症状评分、实验室指标、临床疗效及不良反应发生率。结果:治疗16周后,未成年组与成年组患者的各项临床症状评分[湿疹面积及严重程度指数(EASI)、特应性皮炎评分(SCORAD)、睡眠缺失量表(SLS)及瘙痒数字评分量表(NRS)]均较基线下降,未成年组的治疗有效率(97.2%)高于成年组(76.7%),未成年组的各项临床症状评分[EASI、SCORAD、NRS及视觉模拟评分(VAS)]和血嗜酸性粒细胞(EOS)计数变化率均高于成年组,差异均有统计学意义(P均<0.05)。治疗期间,80例患者中共25例出现轻度不良反应,不良反应总发生率为(31.3%),其中未成年组有14例(37.8%),成年组有11例(25.6%),均未出现与药物相关的严重不良反应。结论:度普利尤单抗可明显改善成年和未成年AD患者的临床症状,且对未成年AD患者症状改善优于成年人。
Objective:To observe and compare the efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis(AD)in adults and minors:Methods:A retrospective analysis was conducted on 80 patients diagnosed with moderate-to-severe AD in the Department of Allergy or Pediatrics at Renji Hospital,Shanghai Jiao Tong University School of Medicine,from March 2020 to October 2024.The patients were divided into a minor group(37 cases)and an adult group(43 cases).All patients were treated with dupilumab for 16 weeks or longer.Clinical symptom scores,laboratory indicators,clinical efficacies,and adverse reaction rates were compared between the two groups,as well as before and after treatment.Results:After 16 weeks of treatment,clinical symptom scores(EASI,SCORAD,SLS,and NRS)in both groups decreased compared to those at baseline.The minor group showed a higher effective rate(97.2%)than the adult group(76.7%).Additionally,the minor group exhibited greater improvements in clinical symptom scores(EASI,SCORAD,NRS,and VAS)and blood EOS count reduction rates compared to the adult group(all P<0.05).During the treatment period,25 out of 80 patients experienced mild adverse reactions,with an overall incidence rate of 31.3%(14 cases,37.8%in the minor group;11 cases,25.6%in the adult group).No serious adverse events related to the medication were observed.Conclusion:Dupilumab significantly improves clinical symptoms in both adult and minor AD patients,with greater improvements observed in minor patients.
作者
王怡玮
丁博
宋洋
徐艳华
张佳卉
郭胤仕
WANG Yiwei;DING Bo;SONG Yang;XU Yanhua;ZHANG Jiahui;GUO Yinshi(Department of Allergy,Renji Hospital Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China;Department of Paediatrics,Renji Hospital Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China)
出处
《临床皮肤科杂志》
北大核心
2025年第11期647-651,共5页
Journal of Clinical Dermatology
基金
上海市卫健委卫生行业临床研究专项基金(20224Y0021)。
作者简介
通信作者:郭胤仕,Email:drguoyinshi@163.com;共同第一作者:王怡玮;共同第一作者:丁博。
